AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 152 min read$RMD

ResMed Stock: Is RMD Underperforming the Healthcare Sector?

ResMed Inc. (RMD), a $31.5B medical device company, trades 23.4% below its 52-week high. Its Q4 2026 revenue rose 8.6% YoY, meeting estimates, while adjusted EPS beat forecasts at $2.95. However, operating margin declined to 30.7% from 33.7% due to higher costs. RMD's stock has fallen 20.5% over the past year, underperforming the healthcare sector ETF XLV. Analysts have a 'Moderate Buy' consensus with a mean price target of $238.20, implying 9.1% upside.

Original reporting
yahoo.com
Published Sep 15, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ResMed Stock: Is RMD Underperforming the Healthcare Sector? — source image
Source · yahoo.com
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

Earnings beat offers limited upside, but margin decline may weigh on valuation.

02

Market read

The article recaps ResMed's Q4 earnings, providing modest insight for traders monitoring healthcare equipment stocks.

03

What to watch

Potential upside from upcoming product launches or cost‑reduction initiatives not covered.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

ResMed is a large‑cap medical device company with recent mixed earnings results.

Company-level read

Ticker impact

$RMDNeutralMedium confidence
Context

Q4 2026 earnings beat EPS and revenue expectations, but margin fell, causing a 5.1% stock decline.

Expected impact

Potential modest rebound if margin concerns ease; downside risk if margin continues to deteriorate.

Evidence & confidence

Positive EPS and revenue offset by lower operating margin; investors may weigh both factors.

Market effects

Sector

Highlights margin pressure in the healthcare equipment sector.

Regional

Limited to US healthcare stocks.

Global

Minimal; reflects company‑specific earnings dynamics.

Counterpoint

What could challenge this read

Margin compression could signal deeper operational issues, suggesting a short bias.

Key entities

  • company
    ResMed Inc.

    Medical device and software provider (ticker RMD).

  • company
    Becton, Dickinson and Company

    Peer referenced for comparative performance.

Read at source← All news

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min